Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antibiotic Commercial Models Under Revision To Tackle Stewardship Tension

Executive Summary

Large pharma companies like AstraZeneca and GSK tout a project to devise new antibiotic development strategies that are independent of sales volumes, while some companies say stewardship and a sales-based system can go hand in hand.

You may also be interested in...



Antibiotic Resistance Gets Attention Of FDA, Congress

Both FDA and Congress are taking interest in combating antibiotic resistance, but FDA likely has more power to make headway in the near term, even as industry remains somewhat wary of that particular agenda item.

Deals Of The Week Ponders When $2.1 Billion Is A Steal

M&A can be expensive, but sometimes deals pay huge dividends. Bristol’s $2.1 billion acquisition of Medarex from 2009 looks like it’ll pay for itself many times over. Plus Actavis buys Warner Chilcott, Novo buys Xellia, and Elan and BTG each keep very busy.

New COVID Treatments Face FDA, Commercial Barriers Despite Ongoing Need

Sponsors want more endpoint clarity as current state of government pandemic response, along with scientific and regulatory hurdles, is constraining efforts to refill a shrinking COVID medicine cabinet and could create vulnerabilities for future pandemics.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS055475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel